Sidoti Equities Analysts Raise Earnings Estimates for Cibus

Posted by George Bondi on May 19th, 2026

Cibus, Inc. (NASDAQ:CBUS – Free Report) – Investment analysts at Sidoti raised their Q2 2026 earnings estimates for shares of Cibus in a report released on Friday, May 15th. Sidoti analyst A. Hantman now anticipates that the company will earn ($0.35) per share for the quarter, up from their prior forecast of ($0.36). The consensus estimate for Cibus’ current full-year earnings is ($1.26) per share. Sidoti also issued estimates for Cibus’ Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.31) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.02) EPS.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group upped their price target on shares of Cibus from $1.90 to $3.00 and gave the company a “hold” rating in a report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.00.

View Our Latest Report on CBUS

Cibus Stock Down 2.3%

NASDAQ:CBUS opened at $1.28 on Tuesday. The company has a fifty day moving average of $2.04 and a 200 day moving average of $1.97. Cibus has a 52 week low of $1.09 and a 52 week high of $4.19. The firm has a market capitalization of $97.70 million, a P/E ratio of -0.65 and a beta of 1.66.

Cibus (NASDAQ:CBUS – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%. The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.61 million.

Institutional Investors Weigh In On Cibus

Institutional investors and hedge funds have recently modified their holdings of the stock. Rockland Trust Co. purchased a new stake in shares of Cibus in the 3rd quarter worth about $26,000. PACK Private Wealth LLC bought a new position in shares of Cibus in the 4th quarter worth about $27,000. Dimensional Fund Advisors LP bought a new position in shares of Cibus in the 1st quarter worth about $33,000. Qube Research & Technologies Ltd bought a new position in shares of Cibus in the 2nd quarter worth about $39,000. Finally, Squarepoint Ops LLC bought a new position in shares of Cibus in the 3rd quarter worth about $62,000. 33.81% of the stock is owned by hedge funds and other institutional investors.

Cibus News Roundup

Here are the key news stories impacting Cibus this week:

Positive Sentiment: Sidoti raised earnings estimates for several upcoming quarters, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, suggesting a modestly better outlook for Cibus’ loss trajectory. Cibus analyst estimate update
Positive Sentiment: Sidoti also improved its FY2027 EPS forecast for Cibus, indicating analysts see some longer-term improvement in profitability. Cibus FY2027 estimate update
Neutral Sentiment: HC Wainwright slightly adjusted some longer-range estimates, with mixed changes across FY2026, FY2027, FY2028, and FY2029, which does not materially change the near-term investment case. Cibus HC Wainwright estimate update
Negative Sentiment: Despite the analyst revisions, Cibus is still expected to post significant losses in the coming years, with full-year 2026 EPS consensus at -$1.26 and FY2027 still projected to be negative at about -$1.02, reinforcing concerns about profitability. Cibus profitability outlook

Cibus Company Profile

(Get Free Report)

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.